home / stock / allr / allr news

ALLR News and Press, Allarity Therapeutics Inc. From 08/10/25

Stock Information
Company Name: Allarity Therapeutics Inc.
Stock Symbol: ALLR
Market: NASDAQ
Website: allarity.com
Menu
ALLR ALLR Quote ALLR Short ALLR News ALLR Articles ALLR Message Board
Get ALLR Alerts

News, Short Squeeze, Breakout and More Instantly...
ALLR - ALLR - Historical Price Movements Surrounding Earnings

2025-08-10 18:45:14 ET Allarity Therapeutics, Inc. (ALLR) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 10.19%. The average open to low on the day of earnings was -5.25%. The average o...
ALLR - Expected US Company Earnings on Monday, August 4th, 2025

Kyndryl Holdings Inc. (KD) is expected to report $0.25 for Q1 2026 Bruker Corporation (BRKR) is expected to report $0.33 for Q2 2025 Vornado Realty Trust (VNO) is expected to report $0.53 for Q2 2025 Diamondback Energy Inc. (FANG) is expected to report $2.63 for Q2 2025 Freightcar...

ALLR - Expected earnings - Allarity Therapeutics Inc.

Allarity Therapeutics Inc. (ALLR) is expected to report $-0.21 for Q2 2025

ALLR - Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

TARPON SPRINGS, Fla., July 15, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor, today ann...
ALLR - Allarity Therapeutics appoints Jeff Ervin as CFO

2025-07-07 08:08:54 ET More on Allarity Therapeutics Financial information for Allarity Therapeutics Read the full article on Seeking Alpha For further details see: Allarity Therapeutics appoints Jeff Ervin as CFO

ALLR - Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a...

ALLR - Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic

TARPON SPRINGS, Fla., June 30, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as ...
ALLR - Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

TARPON SPRINGS, Fla., June 27, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor today anno...

ALLR - Allarity Therapeutics Announces Changes to Board of Directors

TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as ...

ALLR - Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib's Unique, Dual Therapeutic Mechanism of Action

TARPON SPRINGS, Fla., June 4, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a...
Previous 10 Next 10